Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro.

CAS：154229-19-3
中文别名：坦度酮罗;17-(3-吡啶基)雄甾-5,16-二烯-3beta-醇;
英文别名：Abiraterone;(3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol;
分子式：C24H31NO
分子量：349.509
精确质量：349.241
Psa：33.12
Logp：5.3986

MDL号：MFCD00924100

密度：1.14g/cm3
沸点：500.2ºC at 760mmHg
闪点：256.3ºC
折射率：1.605
蒸汽压：7.99E-11mmHg at 25°C

海关编码：2933399090

用途
雄激素拮抗药。